Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: Successful treatment with tigecycline and daptomycin

✍ Scribed by Ian Jenkins

• Book ID: 102346104
• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 44 KB
• Volume: 2
• Category: Article
• ISSN: 1553-5592
• DOI: 10.1002/jhm.236

✦ Synopsis

E nterococci are a leading cause of endocarditis and nosocomial infections. Vancomycin-resistant enterococci (VRE) emerged in the 1980s and now represent most nosocomial isolates in the United States. The first case of VRE endocarditis was reported in 1996. 1 Although increasing enterococcal antibiotic resistance has prompted increasing reliance on newer antibiotics, 2 a recent review of VRE endocarditis noted that survival rates were similar to those for vancomycin-sensitive enterococcal endocarditis. 1 Cure was achieved in several patients with bacteriostatic agents in the absence of valve replacement, but no patients were infected with truly linezolid-resistant organisms. This case of linezolid-resistant VRE endocarditis represents the first reported cure of infective endocarditis with a tigecycline-containing regimen.